HSIC

ANALYST NOTE: HSIC (Henry Schein, Inc.) Date: 2026-06-13 Current Price: $79.92

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Current Price: $79.92 Extension: — Breakout Level: — (Not yet defined) ATR at Breakout: — ATR Current: 2.3% (Sub-threshold) Pivot Strength: —

Analysis:

• Readiness: This is a PARTIAL signal. While the structure is forming, it is not yet actionable on a conservative basis. The current ATR of 2.3% is sub-threshold (below the 4% historical sweet spot), indicating lower volatility and potentially a slower, more grinding accumulation phase rather than an explosive expansion.
• Action: No conservative entry is available. The setup requires a confirmed close above the defined breakout level to transition to "Confirmed-Active."

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Secular Exposure: None Named

At this specific date (2026-06-13), there is no named secular thesis driving this specific trade. This is a TACTICAL setup-led name. The conviction must be derived entirely from the quality of the structural setup (once confirmed) and the underlying business fundamentals as reported by management. We do not invent a macro thesis; we judge the name on its ability to execute its stated operational plan and the technical readiness of the price structure.

3. The Business

Company Overview: Henry Schein, Inc. is a global leader in delivering healthcare products and services, operating through two principal segments: Health Care Distribution and Technology and Value-Added Services.

Business Model & Operations:

• Distribution: The company serves over one million customers worldwide, including dental practitioners, laboratories, physician practices, ambulatory surgery centers, and government/alternative care clinics. It stocks a comprehensive selection of over 300,000 branded and corporate brand products (E8, E14, E15).
• Segments:
• *Health Care Distribution:* Supplies dental goods (consumables, tools, equipment, PPE) and medical supplies (pharmaceuticals, vaccines, surgical instruments, diagnostics) (E21, E23). It also provides equipment repair services through 127 centers worldwide (E17, E22).
• *Technology and Value-Added Services:* Focuses on empowering practices with software (e.g., Dentrix Ascend, Dentale), financial assistance, electronic services, and professional development (E24, E25).
• Market Position: The company is the primary distributor for most national Dental Service Organizations (DSOs) in the U.S. and serves hundreds of thousands of independent private practices with overnight delivery capabilities (E4, E5).

Management Expectations (Source Date: 2026-05-05):

• Financial Guidance: Management expects 2026 full-year total sales growth of approximately 3% to 5% over 2025 (E2).
• Profitability: Non-GAAP diluted EPS is expected to be in the range of $5.23 to $5.37 (E3).
• Strategic Goals: Management has committed to achieving greater than $200 million of annual operating income improvement within the next few years, with a $125 million run rate by the end of 2026 (E1).
• Restructuring: The 2024 Plan of restructuring is expected to be completed by the end of 2027 (E12). Charges recorded in Q1 2026 were $12 million, down from $25 million in the prior year period (E13).
• Growth Drivers: Cloud-based customers increased by roughly 25% year-over-year, with over 13,000 Dentrix Ascend and Dentale subscribers (E7). The shift of procedures to nonacute care settings (ASCs, private practices) aligns with the company's capabilities (E6).

4. Archetype and Conviction

Archetype: Quality Compounder Fit: The name fits the Quality Compounder archetype based on its consistent market leadership, diversified customer base, and management's clear path to margin expansion through operational efficiency and technology adoption.

• Margin Inflector: The commitment to $125 million in operating income run rate by end-2026 and the reduction in restructuring charges ($25M to $12M) indicate a successful margin inflection strategy (E1, E13).
• Valuation Context: Forward consensus EPS for FY1 is $5.35 and FY2 is $5.91 (E26). At a current price of $79.92, the stock trades at approximately 15x FY1 EPS and 13.5x FY2 EPS, suggesting a reasonable valuation for a compounder with double-digit EPS growth expectations.
• Conviction Stack:
• *Thesis Strength:* Low (Tactical only).
• *Evidence Quality:* High (Clear guidance, specific financial targets, strong market position data).
• *Structural Quality:* Moderate (Forming coil, sub-threshold volatility).
• *Setup Readiness:* Low (Awaiting breakout).
• *Rerating Potential:* Moderate (Dependent on successful execution of the $200M operating income goal).

ATR Context: The current ATR of 2.3% is sub-threshold. In the StoryStocks canon, high volatility (4-6%) is the historical sweet spot for breakouts. A sub-threshold ATR suggests the stock is currently in a low-volatility consolidation phase. This supports the "Forming" classification but implies that when the breakout eventually occurs, the move may be slower to develop or require a larger price move to trigger the same volatility expansion.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Execution of Guidance: Confirmation that the $125M operating income run rate is on track ahead of the 2026 year-end.
• Cloud Adoption: Continued acceleration in cloud-based customer growth beyond the reported 25% YoY increase.

What Would Invalidate the Case:

• Guidance Miss: A significant miss on the 3-5% sales growth or EPS guidance for 2026.
• Restructuring Delays: Evidence that the 2024 Plan is not on track for completion by end-2027, or if restructuring charges spike unexpectedly.

Gaps in Evidence:

• Macro Context: No specific macro thesis is attached to this setup; the trade is purely tactical.
• Competitive Landscape: While market share is mentioned, specific data on competitive pressure from new entrants or pricing wars is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management guidance for $125M operating income run rate by end-2026; 25% YoY growth in cloud-based customers; clear path to margin expansion with reduced restructuring charges. Key risks: Sub-threshold ATR (2.3%) indicating low volatility and potential for slow price action; lack of a named secular thesis making the setup purely tactical; structural setup is still forming and not yet actionable. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; do not size based on current forming structure. Expected path: Price likely continues to consolidate within the forming range as management executes the 2026 plan; a breakout is required to trigger a trend. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.